Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from anti-C5 antibody therapy to iptacopan in adults with atypical hemolytic uremic syndrome
2023-504550-35-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Absence of thrombotic microangiopathy manifestation without rescue anti-C5 antibody use. Planned start Apr 2025; status: authorised.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2023-504550-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504550-35-00.